View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRace Oncology 将来の成長Future 基準チェック /26Race Oncologyは、0.1%と34.8%でそれぞれ年率0.1%で利益と収益が成長すると予測される一方、EPSはdeclineで40.2%年率。主要情報0.1%収益成長率-40.20%EPS成長率Biotechs 収益成長25.3%収益成長率34.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日29 Sep 2024今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 05Race Oncology Limited Announces Change of Chief Medical Officer, Effective May 5, 2025Race Oncology Limited announced the appointments of Dr. Jose Iglesias, who succeeds Dr. Michelle Rashford as Chief Medical Officer (CMO), effective 5 May 2025. Dr. Jose Iglesias is an internationally recognized pharmaceutical executive with a distinguished career spanning both major and emerging pharmaceutical companies. His appointment marks a significant addition to Race's clinical leadership team. Dr. Iglesias held key leadership roles at Abraxis BioScience, including Vice President of Global Clinical Development and Chief Medical Officer, where he oversaw the global development of the reformulated chemotherapeutic agent, Abraxane® (paclitaxel) and other pipeline assets. He later served as Vice President of Clinical Development at Celgene, successfully leading several Phase 3 clinical programs for Abraxane® in pancreatic, lung, and metastatic breast cancers. Dr. Iglesias has also held senior medical leadership roles at Amgen, Bionomics, Biothera Pharmaceuticals, Apobiologix, and Eli Lilly, including as Head of Clinical Studies at Eli Lilly Australia. His has extensive experience interacting with global regulatory authorities, reimbursement agencies, oncology cooperative groups, and patient advocacy organizations. He serves as an independent oncology consultant, specializing in solid tumour oncology, immuno-oncology, and translational medicine, with a focus on early to mid-phase clinical development. A widely published expert in oncology, Dr. Iglesias's work has garnered over 12,000 citations.お知らせ • Apr 03Race Oncology Limited Announces RC220 Phase 1 Trial Opens for Patient EnrolmentRace Oncology Limited (Race) announced the site activation of Southside Cancer Care Centre (Miranda, NSW) after receiving governance approval enabling the commencement of patient enrolment for its Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumours patients. This follows the receipt of human ethics approval, undertaking site initiation, and completion of all documentation. The Phase 1 trial will be open label and conducted across multiple sites in Australia, Hong Kong and South Korea. The trial will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose (MTCD) in combination with doxorubicin, and effects on a range of clinical biomarkers including m6A RNA. After an interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The Phase 1 trial will use a Bayesian design enabling greater trial flexibility and speed than traditional approaches. A recent meta-analysis of single agent doxorubicin treatment undertaken by Race Oncology has identified an anticancer response rate to doxorubicin of up to 35% in a wide range of advance and metastatic solid tumour cancers including breast cancer, small cell lung cancer, ovarian cancer, bladder cancer, liver cancer, endometrial cancer, upper gastrointestinal cancer, thyroid cancer, non-small cell lung cancer, and prostate cancer. Preclinical studies by Race Oncology have identified enhancement of the cancer killing activity of doxorubicin by the active anticancer agent in RC220 in 85% of 143 diverse cancer cell lines screened. Timing of first patient enrolment is subject to patient suitability and their interest in participating in the trial.お知らせ • Mar 31Race Oncology Limited Receives HREC Approval from Bellberry to Commence its RC220 Phase 1 Clinical Trial at Gosford and Wyong HospitalsRace Oncology Limited announced that it has received HREC approval from Bellberry to commence its RC220 Phase 1 clinical trial at Gosford and Wyong Hospitals (Central Coast Local Health District). HREC approval allows both the Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation. These approvals are expected during the month of April. The RAC-010 clinical trial is designed to assess the safety, tolerability and pharmacokinetics (PK) of RC220 alone and in combination with doxorubicin, in patients with solid tumours. This approval follows recent HREC approval for the Southside Cancer Centre (Miranda). It is expected HREC approval will be received for additional trial sites in Australia, Hong Kong and South Korea over the following months.お知らせ • Oct 07Race Oncology Limited, Annual General Meeting, Nov 25, 2024Race Oncology Limited, Annual General Meeting, Nov 25, 2024. Location: at the dixon room, state library nsw, 1 shakespeare place, new south wales, australia., sydney Australiaお知らせ • Nov 22Race Oncology Limited Appoints Daniel Tillett as Chief Executive OfficerRace Oncology Limited announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer, effective immediately. Dr Tillett will work alongside Executive Director, Dr Pete Smith, to advance the Company's strategic, clinical and commercialization plans for bisantrene. From September 2019 to March 2023, Dr Tillett was Race's Chief Scientific Officer and Executive Director. He has most recently been working with the Company in a consultancy capacity. In addition to his extensive experience with Race and bisantrene, Dr Tillett brings more than 25 years of experience in the biotech industry and is the founder and CEO of Nucleics, an Australian biotechnology company focused on DNA sequencing and genomics. He was a tenured academic (Senior Lecturer) within the School of Pharmacy and Applied Science at La Trobe University, Australia teaching and researching in the areas of phage therapy (bacterial virology), pharmacy, environmental microbiology, bioinformatics and cancer.お知らせ • Oct 10Race Oncology Limited, Annual General Meeting, Nov 27, 2023Race Oncology Limited, Annual General Meeting, Nov 27, 2023, at 12:00 AUS Eastern Standard Time. Location: the Dixon Room, State Library NSW, 1 Shakespeare Place Sydney New South Wales Australia Agenda: To consider the re-election and appointment of Directors.お知らせ • Aug 22Race Oncology Limited Announces Board ChangesRace Oncology Limited announced changes to the Board and Management team structure, to ensure the company and its lead asset, bisantrene, are suitably positioned for clinical success. Effective immediately, Dr. Peter Smith will step into the role of Executive Director, taking over from Damian Clarke-Bruce, who has tendered his resignation. Non-Executive Director, Dr. John Cullity has advised his intention to retire from the Race Board, following a long and productive tenure.お知らせ • Jun 29Race Oncology Limited Announces Board ChangesRace Oncology Limited announced the appointment of Dr Peter Smith as a Non-Executive Director, replacing Daniel Sharp who has advised his resignation to concentrate on other personal and professional interests. Dr Peter (Pete) Smith has over 30 years of experience in a broad range of activities in the healthcare industry with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private company, Myrio Therapeutics (formerly Affinity Bio.) Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD (later acquired by CSL.) Prior to moving to Australia, Pete co-founded and was CFO of Onyvax Ltd, a cancer immune-therapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC and was involved in numerous transactions including IPOs, fundraisings and M&A. His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. He is currently also a Director of private companies, Hula Therapeutics and Amala Therapeutics.お知らせ • May 09Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023Race Oncology announced the appointment of Dr. Michelle Rashford as Chief Medical Officer (CMO), taking over from Interim CMO, Dr. Ajay Duggal. Dr. Rashford is an internationally experienced biopharmaceutical executive and former physician, with expertise in the successful development and commercialisation of pharmaceuticals across oncology, virology, and immunology. Her 25+ years of drug development experience spans large pharmaceuticals to smaller biotech companies and includes pre-clinical and clinical development, medical and regulatory affairs, and drug commercialisation. Dr. Rashford will join Race Oncology on 1 July 2023 from the Japanese Pharmaceutical company Kyowa Kirin, where she has been the Head of Global Clinical Sciences. Prior to her role at Kyowa Kirin, Dr. Rashford was the Senior Vice President of Clinical Science at Adlai Nortye Biopharma, where she successfully grew the US Clinical Development team and prepared for the company's Phase III trial. She has also held senior roles within global pharmaceutical companies, including five years at Bristol-Myers Squibb and close to 20 years at Roche in a variety of national and global clinical development roles. Dr. Rashford holds a Bachelor of Medicine & Bachelor of Surgery from the University of Tasmania, Australia.お知らせ • Feb 02Race Oncology Limited Appoints Damian Clarke-Bruce as DirectorRace Oncology Limited announced the appointment of Damian Clarke-bruce as Director. Date of appointment is February 1, 2023.お知らせ • Feb 01Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer TrialRace Oncology Limited announced it has received human ethics approval from the Hunter New England Human Research Ethics Committee(NSW, Australia) for the observational stage of a planned Phase 1/2b clinical trial of Zantrene (bisantrene dihydrochloride) in breast cancer patients, to be treated with doxorubicin and cyclophosphamide and who have two or more cardiovascular risk factors. Details of the trial design and purposes have been previously described. Before patients can be enrolled and treated Race must first submit and then receive research institutional governance (site budget and contracting) approval. Submission is expected to take place in the coming weeks. Governance approval is typically received within 4 to 8 weeks of submission. The study will recruit and monitor up to 50 patients being treated for breast cancer using the standard of care (SoC) regimen of doxorubicin (Adriamycin®) and cyclophosphamide - referred to as "AC chemotherapy". The aim of this study is to identify the rate and level of heart damage caused by AC chemotherapy, using modern advanced cardiac imaging and biochemical methods. In addition, the anti-cancer efficacy of AC chemotherapy will be monitored using a liquid biopsy (DNA) approach. The data from this study will be directional for the design of a subsequent Phase 1/2b interventional trial that may help patients to avoid the permanent heart damage that can be caused by AC chemotherapy as well as potentially improving anti-cancer outcomes. These human trials are fully funded from capital raised in December 2021.お知らせ • Jan 19Race Oncology Limited, Annual General Meeting, Feb 21, 2023Race Oncology Limited, Annual General Meeting, Feb 21, 2023, at 10:30 AUS Eastern Standard Time. Location: Race Oncology Limited, Level 36, Gateway Building, 1 Macquarie Place, Sydney NSW 2000 Sydney New South Wales Australia Agenda: To consider and approve issue of options to director - Danny Sharp; to approve issue of options to director Damian Clarke-Bruce; to approve issue of options to director Mary Harney; to approve the increase in total aggregate remuneration for non-executive directors; to consider other matters if any.業績と収益の成長予測OTCPK:RAON.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202711-7-6-616/30/20263-27-27-2716/30/20255-6-6-616/30/20244-14-10-10N/A3/31/20245-12-11-11N/A12/31/20236-11-13-13N/A9/30/20234-11-12-12N/A6/30/20233-10-11-11N/A3/31/20232-10-10-10N/A12/31/20221-11-9-9N/A9/30/20221-11-8-8N/A6/30/20221-11-6-6N/A3/31/20221-10-6-6N/A12/31/20211-9-6-6N/A9/30/20211-8-5-5N/A6/30/20210-6-5-5N/A3/31/20210-5-4-4N/A12/31/20200-4-3-3N/A9/30/20200-4-3-3N/A6/30/20200-4-2-2N/A3/31/20200-3-2-2N/A12/31/20190-3-2-2N/A9/30/20190-3-2-2N/A6/30/20190-4-3-3N/A3/31/20190-4-3-3N/A12/31/20180-5-3-3N/A9/30/20180-6-3-3N/A6/30/20180-6-4-4N/A3/31/20180-6N/A-4N/A12/31/20170-6N/A-4N/A9/30/20170-5N/A-3N/A6/30/2017N/A-4N/A-2N/A3/31/2017N/A-3N/A-2N/A12/31/2016N/A-2N/A-1N/A9/30/2016N/A-1N/A-1N/A6/30/2016N/A0N/A0N/A3/31/2016N/A0N/A0N/A12/31/2015N/A0N/A0N/A9/30/2015N/A0N/A0N/A6/30/2015N/A0N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RAON.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: RAON.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: RAON.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: RAON.Fの収益 ( 34.8% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: RAON.Fの収益 ( 34.8% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RAON.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/08 10:18終値2024/07/11 00:00収益2024/06/30年間収益2024/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Racura Oncology Ltd 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullIndependent Investment Research (Aust.) Pty LtdChris KallosMST Financial Services Pty Limited
お知らせ • May 05Race Oncology Limited Announces Change of Chief Medical Officer, Effective May 5, 2025Race Oncology Limited announced the appointments of Dr. Jose Iglesias, who succeeds Dr. Michelle Rashford as Chief Medical Officer (CMO), effective 5 May 2025. Dr. Jose Iglesias is an internationally recognized pharmaceutical executive with a distinguished career spanning both major and emerging pharmaceutical companies. His appointment marks a significant addition to Race's clinical leadership team. Dr. Iglesias held key leadership roles at Abraxis BioScience, including Vice President of Global Clinical Development and Chief Medical Officer, where he oversaw the global development of the reformulated chemotherapeutic agent, Abraxane® (paclitaxel) and other pipeline assets. He later served as Vice President of Clinical Development at Celgene, successfully leading several Phase 3 clinical programs for Abraxane® in pancreatic, lung, and metastatic breast cancers. Dr. Iglesias has also held senior medical leadership roles at Amgen, Bionomics, Biothera Pharmaceuticals, Apobiologix, and Eli Lilly, including as Head of Clinical Studies at Eli Lilly Australia. His has extensive experience interacting with global regulatory authorities, reimbursement agencies, oncology cooperative groups, and patient advocacy organizations. He serves as an independent oncology consultant, specializing in solid tumour oncology, immuno-oncology, and translational medicine, with a focus on early to mid-phase clinical development. A widely published expert in oncology, Dr. Iglesias's work has garnered over 12,000 citations.
お知らせ • Apr 03Race Oncology Limited Announces RC220 Phase 1 Trial Opens for Patient EnrolmentRace Oncology Limited (Race) announced the site activation of Southside Cancer Care Centre (Miranda, NSW) after receiving governance approval enabling the commencement of patient enrolment for its Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumours patients. This follows the receipt of human ethics approval, undertaking site initiation, and completion of all documentation. The Phase 1 trial will be open label and conducted across multiple sites in Australia, Hong Kong and South Korea. The trial will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose (MTCD) in combination with doxorubicin, and effects on a range of clinical biomarkers including m6A RNA. After an interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The Phase 1 trial will use a Bayesian design enabling greater trial flexibility and speed than traditional approaches. A recent meta-analysis of single agent doxorubicin treatment undertaken by Race Oncology has identified an anticancer response rate to doxorubicin of up to 35% in a wide range of advance and metastatic solid tumour cancers including breast cancer, small cell lung cancer, ovarian cancer, bladder cancer, liver cancer, endometrial cancer, upper gastrointestinal cancer, thyroid cancer, non-small cell lung cancer, and prostate cancer. Preclinical studies by Race Oncology have identified enhancement of the cancer killing activity of doxorubicin by the active anticancer agent in RC220 in 85% of 143 diverse cancer cell lines screened. Timing of first patient enrolment is subject to patient suitability and their interest in participating in the trial.
お知らせ • Mar 31Race Oncology Limited Receives HREC Approval from Bellberry to Commence its RC220 Phase 1 Clinical Trial at Gosford and Wyong HospitalsRace Oncology Limited announced that it has received HREC approval from Bellberry to commence its RC220 Phase 1 clinical trial at Gosford and Wyong Hospitals (Central Coast Local Health District). HREC approval allows both the Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation. These approvals are expected during the month of April. The RAC-010 clinical trial is designed to assess the safety, tolerability and pharmacokinetics (PK) of RC220 alone and in combination with doxorubicin, in patients with solid tumours. This approval follows recent HREC approval for the Southside Cancer Centre (Miranda). It is expected HREC approval will be received for additional trial sites in Australia, Hong Kong and South Korea over the following months.
お知らせ • Oct 07Race Oncology Limited, Annual General Meeting, Nov 25, 2024Race Oncology Limited, Annual General Meeting, Nov 25, 2024. Location: at the dixon room, state library nsw, 1 shakespeare place, new south wales, australia., sydney Australia
お知らせ • Nov 22Race Oncology Limited Appoints Daniel Tillett as Chief Executive OfficerRace Oncology Limited announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer, effective immediately. Dr Tillett will work alongside Executive Director, Dr Pete Smith, to advance the Company's strategic, clinical and commercialization plans for bisantrene. From September 2019 to March 2023, Dr Tillett was Race's Chief Scientific Officer and Executive Director. He has most recently been working with the Company in a consultancy capacity. In addition to his extensive experience with Race and bisantrene, Dr Tillett brings more than 25 years of experience in the biotech industry and is the founder and CEO of Nucleics, an Australian biotechnology company focused on DNA sequencing and genomics. He was a tenured academic (Senior Lecturer) within the School of Pharmacy and Applied Science at La Trobe University, Australia teaching and researching in the areas of phage therapy (bacterial virology), pharmacy, environmental microbiology, bioinformatics and cancer.
お知らせ • Oct 10Race Oncology Limited, Annual General Meeting, Nov 27, 2023Race Oncology Limited, Annual General Meeting, Nov 27, 2023, at 12:00 AUS Eastern Standard Time. Location: the Dixon Room, State Library NSW, 1 Shakespeare Place Sydney New South Wales Australia Agenda: To consider the re-election and appointment of Directors.
お知らせ • Aug 22Race Oncology Limited Announces Board ChangesRace Oncology Limited announced changes to the Board and Management team structure, to ensure the company and its lead asset, bisantrene, are suitably positioned for clinical success. Effective immediately, Dr. Peter Smith will step into the role of Executive Director, taking over from Damian Clarke-Bruce, who has tendered his resignation. Non-Executive Director, Dr. John Cullity has advised his intention to retire from the Race Board, following a long and productive tenure.
お知らせ • Jun 29Race Oncology Limited Announces Board ChangesRace Oncology Limited announced the appointment of Dr Peter Smith as a Non-Executive Director, replacing Daniel Sharp who has advised his resignation to concentrate on other personal and professional interests. Dr Peter (Pete) Smith has over 30 years of experience in a broad range of activities in the healthcare industry with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private company, Myrio Therapeutics (formerly Affinity Bio.) Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD (later acquired by CSL.) Prior to moving to Australia, Pete co-founded and was CFO of Onyvax Ltd, a cancer immune-therapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC and was involved in numerous transactions including IPOs, fundraisings and M&A. His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. He is currently also a Director of private companies, Hula Therapeutics and Amala Therapeutics.
お知らせ • May 09Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023Race Oncology announced the appointment of Dr. Michelle Rashford as Chief Medical Officer (CMO), taking over from Interim CMO, Dr. Ajay Duggal. Dr. Rashford is an internationally experienced biopharmaceutical executive and former physician, with expertise in the successful development and commercialisation of pharmaceuticals across oncology, virology, and immunology. Her 25+ years of drug development experience spans large pharmaceuticals to smaller biotech companies and includes pre-clinical and clinical development, medical and regulatory affairs, and drug commercialisation. Dr. Rashford will join Race Oncology on 1 July 2023 from the Japanese Pharmaceutical company Kyowa Kirin, where she has been the Head of Global Clinical Sciences. Prior to her role at Kyowa Kirin, Dr. Rashford was the Senior Vice President of Clinical Science at Adlai Nortye Biopharma, where she successfully grew the US Clinical Development team and prepared for the company's Phase III trial. She has also held senior roles within global pharmaceutical companies, including five years at Bristol-Myers Squibb and close to 20 years at Roche in a variety of national and global clinical development roles. Dr. Rashford holds a Bachelor of Medicine & Bachelor of Surgery from the University of Tasmania, Australia.
お知らせ • Feb 02Race Oncology Limited Appoints Damian Clarke-Bruce as DirectorRace Oncology Limited announced the appointment of Damian Clarke-bruce as Director. Date of appointment is February 1, 2023.
お知らせ • Feb 01Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer TrialRace Oncology Limited announced it has received human ethics approval from the Hunter New England Human Research Ethics Committee(NSW, Australia) for the observational stage of a planned Phase 1/2b clinical trial of Zantrene (bisantrene dihydrochloride) in breast cancer patients, to be treated with doxorubicin and cyclophosphamide and who have two or more cardiovascular risk factors. Details of the trial design and purposes have been previously described. Before patients can be enrolled and treated Race must first submit and then receive research institutional governance (site budget and contracting) approval. Submission is expected to take place in the coming weeks. Governance approval is typically received within 4 to 8 weeks of submission. The study will recruit and monitor up to 50 patients being treated for breast cancer using the standard of care (SoC) regimen of doxorubicin (Adriamycin®) and cyclophosphamide - referred to as "AC chemotherapy". The aim of this study is to identify the rate and level of heart damage caused by AC chemotherapy, using modern advanced cardiac imaging and biochemical methods. In addition, the anti-cancer efficacy of AC chemotherapy will be monitored using a liquid biopsy (DNA) approach. The data from this study will be directional for the design of a subsequent Phase 1/2b interventional trial that may help patients to avoid the permanent heart damage that can be caused by AC chemotherapy as well as potentially improving anti-cancer outcomes. These human trials are fully funded from capital raised in December 2021.
お知らせ • Jan 19Race Oncology Limited, Annual General Meeting, Feb 21, 2023Race Oncology Limited, Annual General Meeting, Feb 21, 2023, at 10:30 AUS Eastern Standard Time. Location: Race Oncology Limited, Level 36, Gateway Building, 1 Macquarie Place, Sydney NSW 2000 Sydney New South Wales Australia Agenda: To consider and approve issue of options to director - Danny Sharp; to approve issue of options to director Damian Clarke-Bruce; to approve issue of options to director Mary Harney; to approve the increase in total aggregate remuneration for non-executive directors; to consider other matters if any.